How have OTLC shares performed in 2024?

Oncotelic Therapeutics' stock was trading at $0.0383 on January 1st, 2024. Since then, OTLC shares have increased by 4.4% and is now trading at $0.04. View the best growth stocks for 2024 here .

Are investors shorting Oncotelic Therapeutics?

Oncotelic Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 400 shares, a decline of 89.7% from the March 15th total of 3,900 shares. Based on an average trading volume of 136,800 shares, the short-interest ratio is presently 0.0 days. View Oncotelic Therapeutics' Short Interest .

When is Oncotelic Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024. View our OTLC earnings forecast .

How were Oncotelic Therapeutics' earnings last quarter?

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) posted its quarterly earnings results on Thursday, August, 19th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02.

How do I buy shares of Oncotelic Therapeutics?

Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:OTLC

Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free OTLC Stock Alerts

$0.04

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.04
▼
$0.04
50-Day Range: $0.04
▼
$0.05
52-Week Range: $0.01
▼
$0.05

Volume: 35,004 shs
Average Volume: 74,858 shs
Market Capitalization: $15.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Headlines SEC Filings Short Interest

Get Oncotelic Therapeutics alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Oncotelic Therapeutics Stock (OTCMKTS:OTLC)

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

OTLC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OTLC Stock News Headlines

March 25, 2024 | finance.yahoo.com

Linkage of Cancer and Lupus in Gliomas Patients

March 25, 2024 | globenewswire.com

Linkage of Cancer and Lupus in Gliomas Patients

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

March 4, 2024 | globenewswire.com

Invitation to Participate in STOP-PC Clinical Trial

February 22, 2024 | benzinga.com

Oncotelic Therapeutics Stock (OTC:OTLC) Earnings Dates and Earning Calls

February 3, 2024 | msn.com

Oncotelic Therapeutics Strikes Material Definitive Legal Agreement

January 23, 2024 | morningstar.com

Lineage Cell Therapeutics Inc LCTX

December 18, 2023 | finance.yahoo.com

Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

November 15, 2023 | finanznachrichten.de

Oncotelic Therapeutics, Inc.: Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results

November 15, 2023 | msn.com

Oncotelic Therapeutics reports Q3 results

November 15, 2023 | finance.yahoo.com

Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results

September 11, 2023 | benzinga.com

The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge

September 11, 2023 | benzinga.com

The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The Charge

August 25, 2023 | finance.yahoo.com

Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023

August 23, 2023 | finance.yahoo.com

Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer

May 16, 2023 | finance.yahoo.com

Oncotelic Participating at 2023 BIO International Convention

April 24, 2023 | technews.tmcnet.com

Oncotelic Launches PDAO SEC Chatbot

April 20, 2023 | seekingalpha.com

Oncotelic Therapeutics reports FY results

April 19, 2023 | finance.yahoo.com

Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology

March 13, 2023 | technews.tmcnet.com

High Intra-Tumor TGF-ß2 Predicts Poor Survival in Pediatric Cancer of the Brainstem

February 15, 2023 | seekingalpha.com

OTLC Oncotelic Therapeutics, Inc.

February 6, 2023 | finance.yahoo.com

Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer

January 25, 2023 | finance.yahoo.com

Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer

December 28, 2022 | finance.yahoo.com

Oncotelic Issues Year End Message to Shareholders

November 8, 2022 | finance.yahoo.com

Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas

September 28, 2022 | finance.yahoo.com

Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting

See More Headlines

Receive OTLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/19/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/17/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:OTLC
CUSIP: N/A
CIK: 908259
Web: www.mateon.com
Phone: (650) 635-7000
Fax: 650-635-7001
Employees: 22
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,900,000.00
Net Margins: N/A
Pretax Margin: -18,228.48%
Return on Equity: -55.34%
Return on Assets: -24.44%

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 0.02
Quick Ratio: 0.02

Sales & Book Value

Annual Sales: $70,000.00
Price / Sales: 239.20
Cash Flow: $0.01 per share
Price / Cash Flow: 3.21
Book Value: $0.05 per share
Price / Book: 0.84

Miscellaneous

Outstanding Shares: 398,670,000
Free Float: 242,309,000
Market Cap: $16.74 million
Optionable: Not Optionable
Beta: 0.13

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Vuong Trieu Ph.D. (Age 61)
Chairman & CEO
Comp: $75.5k
Mr. Amit Shah (Age 57)
Chief Financial Officer
Comp: $40.44k
Dr. Anthony E. Maida III (Age 72)
B.A., MA, MBA, Ph.D., Chief Clinical Officer of Translational Medicine & Director
Comp: $75k
Mr. Saranjit Saund (Age 66)
CBO & GM of AI Division
Comp: $35.43k
Mr. Steven W. King (Age 60)
Consultant & Director
Dr. Larn Hwang (Age 61)
Chief Scientific Officer
Dr. Seymour Howard Fein M.D. (Age 75)
Chief Medical Officer
Mr. Burcak Beser
CTO of AI Division

Key Competitors

View All Competitors

OTLC Stock Analysis - Frequently Asked Questions

How have OTLC shares performed in 2024?: Oncotelic Therapeutics' stock was trading at $0.0383 on January 1st, 2024. Since then, OTLC shares have increased by 4.4% and is now trading at $0.04.
View the best growth stocks for 2024 here.
Are investors shorting Oncotelic Therapeutics?: Oncotelic Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 400 shares, a decline of 89.7% from the March 15th total of 3,900 shares. Based on an average trading volume of 136,800 shares, the short-interest ratio is presently 0.0 days.
View Oncotelic Therapeutics' Short Interest.
When is Oncotelic Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024.
View our OTLC earnings forecast.

How were Oncotelic Therapeutics' earnings last quarter?: Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) posted its quarterly earnings results on Thursday, August, 19th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02.
How do I buy shares of Oncotelic Therapeutics?: Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OTLC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial